IP Library Granted Patent US 9,486,413
Granted Patent B2
US 9,486,413 · App. 14/729,675 · Granted Nov 8, 2016

Tamper resistant dosage forms

Inventors: William H. McKenna (Yonkers, NY); Richard O. Mannion (Furlong, PA); Edward P. O'Donnell (Basking Ridge, NJ); Haiyong H. Huang (Princeton, NJ)
Assignees: PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P.
A61K9/28A61J3/06A61J3/10A61K9/0002A61K9/1641A61K9/209A61K9/2013A61K9/2018A61K9/2031A61K9/2054A61K9/2077A61K9/2095A61K9/2853A61K9/2866A61K9/2893A61K31/485A61K45/06A61K47/10A61K47/34B29C43/003A61K9/2072
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,486,413
App. No.
14/729,675
Granted
Nov 8, 2016
Kind
B2
Abstract

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Claims (37)

1. A cured shaped pharmaceutical tablet comprising:

(1) at least a first compression shaped and then air cured matrix, wherein said curing is without compression, by heated air having a temperature of at least about 62° C. for a duration of at least about 5 minutes, said matrix comprising hydrocodone or a pharmaceutically acceptable salt thereof in combination with at least one high molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight selected from 4,000,000, 7,000,000, and a combination thereof, and optionally further comprising at least one low molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000;

(2) optionally a second air cured matrix comprising an hydrocodone or a pharmaceutically acceptable salt thereof in combination with at least one low molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000; and

(3) optionally a coating,

wherein, in said tablet

said high molecular weight polyethylene oxide is at least 54% by weight of the total weight of said uncoated tablet;

said low molecular weight polyethylene oxide, if present, is at least 10% by weight of the total weight of said uncoated tablet; and

said tablet provides a once-daily extended release of hydrocodone or pharmaceutically acceptable salt thereof from said tablet.

2. A cured shaped tablet as defined in claim 1 , wherein said hydrocodone or pharmaceutical salt thereof comprises at least 2.4% by weight, based upon the total weight of said uncoated tablet.

3. A cured shaped tablet as defined in claim 1 , wherein each shaped and cured matrix has been cured by heated air having a temperature of about 62° C. to about 90° C. for a duration of about 15 minutes to about 10 hours, and then is subsequently cooled.

4. A cured shaped tablet as defined in claim 3 , wherein said heated air temperature is from about 65° C. to about 90° C., said duration is about 15 minutes to about 8 hours, and said cooling comprises exposure to an air temperature of less than about 62° C.

5. A cured shaped tablet as defined in claim 1 , wherein said shaped tablet is coated at least one of before or after being cured.

6. A cured shaped tablet as defined in claim 4 , wherein one or both of said first matrix and second matrix further comprise a coating.

7. A cured shaped tablet as defined in claim 1 , wherein, said second matrix is present and said low molecular weight polyethylene oxide comprises at least about 20% by weight of the total weight of said uncoated tablet.

8. A cured shaped tablet as defined in claim 6 , wherein, said second matrix is present and said low molecular weight polyethylene oxide comprises at least about 20% by weight of the total weight of said uncoated tablet.

9. A cured shaped tablet as defined in claim 7 , wherein said low molecular weight polyethylene oxide is at least 22% by weight based upon the total weight of said uncoated tablet and said hydrocodone or pharmaceutically acceptable salt is at least 2.4% by weight based upon the total weight of said uncoated tablet.

10. A cured shaped tablet as defined in claim 6 , wherein the total combined weight of said high and low molecular weight polyethylene oxide is at least 60% by weight, based upon the total weight of said uncoated tablet.

11. A cured shaped tablet as defined in claim 6 , wherein the total combined weight of said high and low molecular weight polyethylene oxide is at least 65% by weight, based upon the total weight of said uncoated tablet.

12. A cured shaped tablet as defined in claim 6 , wherein the total combined weight of said high and low molecular weight polyethylene oxide is at least 80% by weight, based upon the total weight of said uncoated tablet.

13. A cured shaped tablet as defined in claim 6 , wherein the total combined weight of said high and low molecular weight polyethylene oxide is at least 85% by weight, based upon the total weight of said uncoated tablet.

14. A cured shaped tablet as defined in claim 6 , wherein the total combined weight of said high and low molecular weight polyethylene oxide is at least 90% by weight, based upon the total weight of said uncoated tablet.

15. A cured shaped tablet as defined in claim 6 , wherein said tablet further comprises magnesium stearate.

16. A cured shaped tablet as defined in claim 15 , wherein said tablet further comprises butylated hydroxytoluene.

17. A cured shaped tablet as defined in claim 15 , wherein said tablet further comprises at least one of lactose, microcrystalline cellulose and hydroxypropyl cellulose.

18. A cured shaped tablet as defined in claim 1 , wherein said tablet, when subjected to an indentation test, has at least one of (i) a cracking force of at least 110 N; and (ii) a penetration depth to crack distance of at least 1.0 mm.

19. A cured shaped tablet as defined in claim 1 , wherein said tablet can be flattened to a thickness that is no more than about 60% of the initial tablet thickness without breaking; and said flattened tablet swells upon exposure to water or ethanol.

20. A cured shaped tablet according to claim 1 , wherein, after a plurality of at least 100 of the same tablets are stored at 40° C. and 75% relative humidity for at least 3 months, a set of at least ten of said stored tablets, on average, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C., in the absence of an added stabilizer, release an amount of said hydrocodone or pharmaceutical salt thereof, after 1 hour, 4 hours, and 12 hours, that deviates from an initial dosage amount of said hydrocodone or pharmaceutically acceptable salt thereof by no more than about 10% points.

21. A cured shaped tablet as defined in claim 3 , wherein said air temperature during curing exhibits a plateau profile.

22. A cured shaped tablet as defined in claim 4 , wherein said air temperature during curing exhibits a plateau profile.

23. A cured shaped tablet as defined in claim 3 , wherein said air temperature during curing exhibits a parabolic or triangular profile.

24. A cured shaped tablet as defined in claim 4 , wherein said air temperature during curing exhibits a parabolic or triangular profile.

25. A cured shaped tablet as defined in claim 3 , wherein curing is by convection and said air temperature is measured as a mean exhaust temperature of a convection curing device.

26. A cured shaped tablet as defined in claim 3 , wherein curing is by convection at atmospheric pressure and said air temperature is measured as a mean exhaust temperature of a convection curing device.

27. A cured shaped tablet as defined in claim 4 , wherein curing is by convection at atmospheric pressure and said air temperature is measured as a mean exhaust temperature of a convection curing device.

28. A cured shaped tablet as defined in claim 19 , wherein said tablet, when subjected to an indentation test, has at least one of (i) a cracking force of at least 110 N; and (ii) a penetration depth to crack distance of at least 1.0 mm.

29. A cured shaped tablet as defined in claim 1 wherein said cured shaped tablet has a density that is at least about 1% lower than the density of said shaped tablet prior to curing.

30. A cured shaped tablet as defined in claim 4 wherein said cured shaped tablet has a density that is at least about 1% lower than the density of said shaped tablet prior to curing.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2026
From: PURDUE PHARMA L.P
To: KNOA PHARMA LLC
Reel/Frame 075645/0702 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2017
From: MCKENNA, WILLIAM H.; MANNION, RICHARD O.; O'DONNELL, EDWARD P.; HUANG, HAIYONG H.
To: PURDUE PHARMA L.P.
Reel/Frame 043148/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2015
From: PURDUE PHARMA L.P.
To: PURDUE PHARMA L.P.; PURDUE PHARMACEUTICALS L.P.
Reel/Frame 035818/0788 →
Continuity (5)
Continuation 14515924 · Oct 16, 2014
Continuation 13803132 · Mar 14, 2013
Division 11844872 · Aug 24, 2007
Provisional Application 60840244 · Aug 25, 2006
Related Publication 20150265601A1 · Sep 24, 2015